Do you write news releases? And want help?
We offer free pre-publication review of releases. SEE MORE →
You can’t do much in a 176-word story, and Reuters didn’t in this one.
The story didn’t tell readers this was an observational study–cause-and-effect couldn’t be established.
The story is full of holes and canned quotes, making the news release more informative.
When it comes to ketamine, people with depression and their families should be informed of the unclear benefits and risks.
Also, the story states that Xofluza is associated with fewer side effects than Tamiflu, but it doesn’t mention any potential harms.
The story provides people with the fundamental details they need to be informed patients.
The story conflates progression-free survival with overall survival.
Thankfully, the story did mention the extremely steep cost of these drugs.
But the story did a good job of reporting on the cost and availability of this procedure.
It would have been helpful if the story had explored who would pay for this kind of screening, and what we know about depression screening in general: Is it effective?
Tips & Resources for Analyzing Health Care Claims